BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Barake F, Soza A, González A. Galectins in the brain: advances in neuroinflammation, neuroprotection and therapeutic opportunities. Current Opinion in Neurology 2020;33:381-90. [DOI: 10.1097/wco.0000000000000812] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 van Klaveren S, Dernovšek J, Jakopin Ž, Anderluh M, Leffler H, Nilsson UJ, Tomašič T. Design and synthesis of novel 3-triazolyl-1-thiogalactosides as galectin-1, -3 and -8 inhibitors. RSC Adv 2022;12:18973-84. [PMID: 35873334 DOI: 10.1039/d2ra03163a] [Reference Citation Analysis]
2 Ramírez Hernández E, Alanis Olvera B, Carmona González D, Guerrero Marín O, Pantoja Mercado D, Valencia Gil L, Hernández-Zimbrón LF, Sánchez Salgado JL, Limón ID, Zenteno E. Neuroinflammation and galectins: a key relationship in neurodegenerative diseases. Glycoconj J 2022. [PMID: 35653015 DOI: 10.1007/s10719-022-10064-w] [Reference Citation Analysis]
3 Nio-Kobayashi J, Itabashi T. Galectins and Their Ligand Glycoconjugates in the Central Nervous System Under Physiological and Pathological Conditions. Front Neuroanat 2021;15:767330. [PMID: 34720894 DOI: 10.3389/fnana.2021.767330] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
4 Tan Y, Zheng Y, Xu D, Sun Z, Yang H, Yin Q. Galectin-3: a key player in microglia-mediated neuroinflammation and Alzheimer's disease. Cell Biosci 2021;11:78. [PMID: 33906678 DOI: 10.1186/s13578-021-00592-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
5 Perlman SL. Update on the Treatment of Ataxia: Medication and Emerging Therapies. Neurotherapeutics 2020;17:1660-4. [PMID: 33021724 DOI: 10.1007/s13311-020-00941-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]